Medicare OKs esketamine therapy for major depression, but prepare for hurdles
An interim final rule with comment period in the final 2020 Medicare physician fee schedule creates a new service for patients with depression who have not responded to oral anti-depressants. However, the treatments will include some unusual rules for practices and patients.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.
Quick, Current, Complete - www.findacode.com